Press Release Archive
Press Releases
February 2023
02.28.2023 Vaccines Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults 02.27.2023 Financial Finance Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference 02.24.2023 Vaccines Covid-19 Vaccines Pfizer and BioNTech Submit Supplemental Biologics License Application for U.S. FDA Approval of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine for Ages 12 Years and Older as Primary Series or Booster 02.22.2023 Medicines Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance 02.21.2023 Vaccines Vaccines U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review 02.16.2023 Medicines Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study 02.16.2023 Medicines Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults 02.10.2023 Medicines FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib) 02.09.2023 Financial Finance Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
January 2023
01.31.2023 Financial Finance PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE 01.17.2023 Responsibility Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries 01.06.2023 Vaccines U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.